Honghui Hu

Honghui is a partner and a senior patent counsel at Wanhuida Intellectual Property. She is qualified as a patent attorney and as a lawyer in China.

Honghui has abundant experience in prosecuting and litigating patent- and technology-related matters, with her technical expertise primarily focusing on chemistry, biotech, pharmaceutical, and food technology. She excels in advising clients on intricate matters such as patent validity analysis, freedom-to-operate, and infringement risk assessment. Honghui is a sought-after counsel for her expertise in handling complex patent matters concerning validity and infringement litigations. She frequently advises multinational corporations in the pharmaceutical, biotech, and chemistry industries.

Honghui is one of the lead counsels that helped to defend the validity of Bayer’s compound patent of the blockbuster anticoagulant drug rivaroxaban, a case selected as one of the CNIPA’s Top Ten Patent Reexamination and Invalidation Cases in 2020.